{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:01:25Z","timestamp":1794013285338,"version":"4.8.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Young Scholars of Yangtze River Scholar Professor Program","award":["2023 BW"],"award-info":[{"award-number":["2023 BW"]}]},{"name":"Foundation of Jiangsu Commission of Health","award":["M2021048"],"award-info":[{"award-number":["M2021048"]}]},{"name":"Project of Taizhou Clinical Medical School of Nanjing Medical University","award":["TZKY20220209"],"award-info":[{"award-number":["TZKY20220209"]}]},{"name":"Changzhou Sci\uff06Tech Program","award":["CJ20235048"],"award-info":[{"award-number":["CJ20235048"]}]},{"name":"Science and Technology Project of Changzhou Health Commission","award":["QY202304"],"award-info":[{"award-number":["QY202304"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04347-1","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T08:55:34Z","timestamp":1755593734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Haixia","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"11","key":"4347_CR1","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","volume":"18","author":"K Matsushita","year":"2022","unstructured":"Matsushita K, Ballew SH, Wang AY, Kalyesubula R, Schaeffner E, Agarwal R. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022;18(11):696\u2013707.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4347_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10557-020-07020-x","volume":"35","author":"RO Mathew","year":"2021","unstructured":"Mathew RO, Rosenson RS, Lyubarova R, Chaudhry R, Costa SP, Bangalore S, Sidhu MS. Concepts and controversies: lipid management in patients with chronic kidney disease. Cardiovasc Drugs Ther. 2021;35(3):479\u201389.","journal-title":"Cardiovasc Drugs Ther"},{"key":"4347_CR3","doi-asserted-by":"publisher","unstructured":"Zheng-Lin B, Ortiz AJD. Lipid management in chronic kidney disease: systematic review of PCSK9 targeting. Drugs. 2018;78(2):215\u201329. https:\/\/doi.org\/10.1007\/s40265-017-0858-2.","DOI":"10.1007\/s40265-017-0858-2"},{"key":"4347_CR4","doi-asserted-by":"publisher","unstructured":"Harper C, Jacobson TJC. Evidence-based management of Statin myopathy. Curr Atheroscler Rep. 2010;12(5):322\u201330. https:\/\/doi.org\/10.1007\/s11883-010-0120-9.","DOI":"10.1007\/s11883-010-0120-9"},{"issue":"3","key":"4347_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"RS Rosenson","year":"2018","unstructured":"Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72(3):314\u201329.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"4347_CR6","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4997\/JRCPE.2017.212","volume":"47","author":"S Hadjiphilippou","year":"2017","unstructured":"Hadjiphilippou S, Ray KK. Evolocumab and clinical outcomes in patients with cardiovascular disease. J Royal Coll Physicians Edinb. 2017;47(2):153\u20135.","journal-title":"J Royal Coll Physicians Edinb"},{"issue":"22","key":"4347_CR7","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"key":"4347_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pharmtox-010716-104944","volume":"57","author":"AC Burke","year":"2017","unstructured":"Burke AC, Dron JS, Hegele RA, Huff MW. PCSK9: regulation and target for drug development for dyslipidemia. Annu Rev Pharmacol Toxicol. 2017;57:223\u201344.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"16","key":"4347_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, et al. Efficacy and safety of Alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"issue":"7","key":"4347_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/14779072.2017.1348231","volume":"15","author":"EA Stein","year":"2017","unstructured":"Stein EA, Turner TA. Are the PCSK9 inhibitors the panacea of atherosclerosis treatment? Expert Rev Cardiovasc Ther. 2017;15(7):491\u20134.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"5","key":"4347_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","volume":"114","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA. Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150\u00a0mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;114(5):711\u20135.","journal-title":"Am J Cardiol"},{"issue":"1","key":"4347_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40256-018-0303-2","volume":"19","author":"YX Cao","year":"2019","unstructured":"Cao YX, Liu HH, Li S, Li JJ. A Meta-Analysis of the effect of PCSK9-Monoclonal antibodies on Circulating lipoprotein (a) levels. Am J Cardiovasc Drugs: Drugs Devices Other Interventions. 2019;19(1):87\u201397.","journal-title":"Am J Cardiovasc Drugs: Drugs Devices Other Interventions"},{"key":"4347_CR13","doi-asserted-by":"crossref","unstructured":"Correction to, NLA\/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2023;148(7):e5. \/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/. 2018 AHA\/ACC\/AACVPR\/AAPA.","DOI":"10.1161\/CIR.0000000000001172"},{"issue":"10075","key":"4347_CR14","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet (London England). 2017;389(10075):1238\u201352.","journal-title":"Lancet (London England)"},{"issue":"12","key":"4347_CR15","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1097\/TP.0000000000004234","volume":"106","author":"P Delanaye","year":"2022","unstructured":"Delanaye P, Masson I, Maillard N, Pottel H, Mariat C. The new 2021 CKD-EPI equation without race in a European cohort of renal transplanted patients. Transplantation. 2022;106(12):2443\u20137.","journal-title":"Transplantation"},{"key":"4347_CR16","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139(25):e1082-e1143.","DOI":"10.1161\/CIR.0000000000000624"},{"key":"4347_CR17","doi-asserted-by":"publisher","unstructured":"Ferro C, Mark P, Kanbay M, Sarafidis P, Heine G, Rossignol P, Massy Z, Mallamaci F, Valdivielso J, Malyszko J et al. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol. 2018;14(12):727\u201349. https:\/\/doi.org\/10.1038\/s41581-018-0072-9.","DOI":"10.1038\/s41581-018-0072-9"},{"key":"4347_CR18","doi-asserted-by":"publisher","unstructured":"Charytan D, Sabatine M, Pedersen T, Im K, Park J, Pineda A, Wasserman S, Deedwania P, Olsson A, Sever P et al. Efficacy and safety of Evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol. 2019;73(23):2961\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2019.06.041.","DOI":"10.1016\/j.jacc.2019.06.041"},{"key":"4347_CR19","doi-asserted-by":"publisher","unstructured":"Toth P, Dwyer J, Cannon C, Colhoun H, Rader D, Upadhyay A, Louie M, Koren A, Letierce A, Mandel J et al. Efficacy and safety of lipid Lowering by Alirocumab in chronic kidney disease. Kidney Int. 2018;93(6):1397\u2013408. https:\/\/doi.org\/10.1016\/j.kint.2017.12.011.","DOI":"10.1016\/j.kint.2017.12.011"},{"key":"4347_CR20","doi-asserted-by":"publisher","unstructured":"Bajaj A, Damrauer S, Anderson A, Xie D, Budoff M, Go A, He J, Lash J, Ojo A, Post W et al. Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic renal insufficiency Cohort). Arterioscler Thromb Vasc Biol. 2017;37(10):1971\u20138. https:\/\/doi.org\/10.1161\/ATVBAHA.117.309920.","DOI":"10.1161\/ATVBAHA.117.309920"},{"key":"4347_CR21","doi-asserted-by":"publisher","unstructured":"Fernandez-Prado R, Perez-Gomez M, Ortiz AJC. Pelacarsen for Lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J. 2020;13(5):753\u20137. https:\/\/doi.org\/10.1093\/ckj\/sfaa001.","DOI":"10.1093\/ckj\/sfaa001"},{"issue":"1","key":"4347_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","volume":"15","author":"RM Stoekenbroek","year":"2018","unstructured":"Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology beyond LDL control. Nat Reviews Endocrinol. 2018;15(1):52\u201362.","journal-title":"Nat Reviews Endocrinol"},{"key":"4347_CR23","doi-asserted-by":"publisher","unstructured":"Jin K, Park B, Kim Y, Vaziri NJANKF. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014;63(4):584\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2013.10.042.","DOI":"10.1053\/j.ajkd.2013.10.042"},{"key":"4347_CR24","doi-asserted-by":"publisher","unstructured":"Skeby C, Hummelgaard S, Gustafsen C, Petrillo F, Frederiksen K, Olsen D, Kristensen T, Ivarsen P, Madsen P, Christensen E et al. Proprotein convertase subtilisin\/kexin type 9 targets Megalin in the kidney proximal tubule and aggravates proteinuria in nephrotic syndrome. Kidney Int. 2023; 104(4):754\u201368. https:\/\/doi.org\/10.1016\/j.kint.2023.06.024.","DOI":"10.1016\/j.kint.2023.06.024"},{"key":"4347_CR25","doi-asserted-by":"publisher","unstructured":"Strilchuk L, Fogacci F, Cicero, AJEoods. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019;18(7):611\u201321. https:\/\/doi.org\/10.1080\/14740338.2019.1620730.","DOI":"10.1080\/14740338.2019.1620730"},{"key":"4347_CR26","doi-asserted-by":"publisher","unstructured":"O\u2019Donoghue M, Giugliano R, Wiviott S, Atar D, Keech A, Kuder J, Im K, Murphy S, Flores-Arredondo J, L\u00f3pez J et al. Long-Term Evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620.","DOI":"10.1161\/CIRCULATIONAHA.122.061620"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04347-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04347-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T16:57:54Z","timestamp":1757437074000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04347-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4347"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04347-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"29 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Zhong Da Hospital (2023ZDSYLL264-P01), and its protocol adheres to the Declaration of Helsinki. Informed consent was exempt because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors have read and agreed to the published version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"472"}}